Events

Nonclinical Safety Studies for Investigational New Drug and New Drug Application Filing for Small Molecules Part 2: Genetic Toxicology/Carcinogenicity and Reproductive and Developmental Toxicology

Hosted by: The SOT Women in Toxicology Special Interest Group and the Carcinogenesis Specialty Section

In two parts, this webinar will cover the different types of toxicology studies conducted to support Investigational New Drug (IND) and New Drug Application (NDA) filings for small molecules, including an overview of the nonclinical modules, safety pharmacology, genetic toxicology, carcinogenicity, and reproductive and developmental toxicology. This webinar will cover best practices and example case studies from leaders in the field. Part 1 is in collaboration with the Drug Discovery Toxicology Specialty Section and Part 2 is with the Carcinogenesis Specialty Section.

Speakers:
Smita Salian-Mehta, PhD, DABT, ERT, Senior Project Toxicologist, Gilead Sciences
Dinah Misner, PhD, DABT, DSP, Vice President, Aligos Therapeutics
Toufan Parman, PhD, DABT, Senior Director of Nonclinical Safety Evaluation, Sangamo Therapeutics
Ellen McGlinchey, PhD, Senior Project Toxicologist, Gilead Sciences

Materials:
Webinar Recording and Materials

A Deeper Understanding of Chemical Early Carcinogenesis for the Development of New and More Effective Preventive Strategies

Hosted by: The SOT Carcinogenesis and Molecular and Systems Biology Specialty Sections and the Toxicologists of African Origin Special Interest Group

Presenter(s): Jesse Salk, PhD, MD, Assistant Professor, University of Washington, Justin Colacino, PhD, MA, MPH, Associate Professor, University of Michigan, and Melissa Troester, PhD, Professor, University of North Carolina (UNC), Center for Environmental Health and Susceptibility, UNC Lineberger Comprehensive Cancer Center

Materials:
Webinar Recording and Materials